Andrew Cheng, Akero CEO

NASH-fo­cused Akero Ther­a­peu­tics ex­tends its run­way by an­oth­er year with Pfiz­er's help

Two years ago, Akero Ther­a­peu­tics laid out what one an­a­lyst called the “best-in-class NASH da­ta so far” in a field lit­tered with tri­al fail­ures and am­bigu­ous read­outs. Fol­low­ing those in­ter­im Phase II re­sults, Akero em­barked on a larg­er Phase II tri­al that is sup­posed to re­port out lat­er this year.

But things weren’t look­ing up for the San Fran­cis­co-based biotech when it re­vealed in its Q1 earn­ings re­port that it had just a year and a half of cash left — not enough to push its drug in­to piv­otal Phase III clin­i­cal tri­als that would sup­port an FDA ap­proval.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.